Scientific Plenary II: Challenges in Cancer Care Delivery

Scientific Plenary

Moderators:

  • Kemi Doll, MD MSCR, University of Washington, Seattle, WA
  • Christine Fisher, MD, University of Colorado, Aurora, CO

Distillant:

  • Ruth Carlos, MD, University of Michigan, Ann Arbor, MI

Distillant:

  • Catheryn Yashar, MD, University of California, San Diego, La Jolla, CA

Location: Kamehameha 3

Description:
This session will feature abstracts on financial toxicity that span the socioeconomic spectrum, the impact of variation in quality of cervical cancer treatment at the national level, and an international perspective on HPV vaccination and the influence of governmental support.

ABSTRACT 8
The cost of treatment: Financial toxicity and opportunity costs among gynecologic cancer patients starting a new line of treatment

M.I. Liang, S.S. Summerlin, A.C. Cohen, T.K.L. Boitano, H.J. Smith, M. Pisu, S. Bhatia and W. Huh
University of Alabama at Birmingham, Birmingham, AL, USA

ABSTRACT 9
Impact of financial assistance programs on time to completion of therapy in women receiving chemoradiation for cervical cancer

J. Gillen1, S. Grimes1, K.G. Essel1, G. Duininck1, D. Zhao1, J.S. Thompson2 and D.L. Richardson2
1The University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA 2The University of Oklahoma, Stephenson Cancer Center, Oklahoma City, OK, USA

ABSTRACT 10
Better late than never: Brachytherapy is more important than timeframe in cervical cancer outcomes

T. K. Korenaga1, W. Pierson1, M. Swanson2, J. S. Chapman3, L. Chen3
1University of California, San Francisco, San Francisco, CA, USA, 2UCSF School of Medicine, San Francisco, CA, USA, 3UCSF Helen Diller Comprehensive Cancer Center, San Francisco, CA, USA

ABSTRACT 11
Disparities in utilization and timing of brachytherapy for patients with locally advanced cervical cancer: A National Cancer Database study

S. Alimena1, D. Yang2, A. Melamed3, L. Lee4, M. Worley4, S. Feldman5, K. M. Elias4, P. Orio4, M. King4
1Brigham and Women’s Hospital/Harvard Medical School, Boston, MA, USA, Massachusetts General Hospital, Boston, MA, USA, 2Harvard Medical School, Boston, MA, USA, 3Massachusetts General Hospital, Boston, MA, USA, 4Brigham and Women’s Hospital/Harvard Medical School, Boston, MA, USA, Dana-Farber Cancer Institute, Boston, MA, USA, 5Brigham and Women’s Hospital/Harvard Medical School, Boston, MA, USA

ABSTRACT 12
Epidemiologic profile of type specific human papillomavirus (HPV) infection after initiation of HPV vaccination in Japanese girls

M. Sekine1, M. Yamaguchi1, R. Kudo1, S. Adachi2, Y. Ueda3, S.J.B. Hanley4 and T. Enomoto2
1Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan, 2Niigata University Graduate School of Medicine, Niigata, Japan, 3Osaka University Graduate School of Medicine, Osaka, Japan, 4Hokkaido University Graduate School of Medicine, Sapporo, Japan

ABSTRACT 13
HPV vaccination uptake associated with HPV-related cancer incidence but not rurality in the Deep South: Does perceived risk outweigh access concerns?

J.Y. Pierce, M.J. Vickers, C. Green, J.M. Scalici and C.L. Daniel
Mitchell Cancer Institute, University of South Alabama, Mobile, AL, USA

Top